Evidence map›Paper›PMID 41054859›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.

Jun-Ze Liang, Youtao Wang, Cong Sun, Tao Liu, Zengfeng Wu, Lipeng Chen, Lina Chen, Penglin Li, Zhengkang Li, Cangui Zhang and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Frontiers in immunology · 2026
    Review
  3. B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jun-Ze LiangDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Youtao WangDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Cong SunDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Tao LiuDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zengfeng WuDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Lipeng ChenDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Lina ChenDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Penglin LiDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zhengkang LiLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Cangui ZhangDepartment of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Bingyun LuDepartment of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Ye ChenDepartment of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Bing GuLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Qian ZhongDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Mu-Sheng ZengDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Jinping LiuDepartment of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.ORCID https://orcid.org/0000-0002-4854-1610

Funding

Fundamental Research Funds for the Central Universities of Sun Yat-sen University 23hytd014National Natural Science Foundation of China 21HAA02056National Natural Science Foundation of China 82373257Young Talents Program of Sun Yat-sen University Cancer Center YTP-SYSUCC-0056
6 · The paper itself

Abstract

Vaccine development for pathogens has faced significant challenges, contributing to a public health burden. B-cell epitope (BCE) prediction is a crucial process in vaccine development, but is hindered by limited efficiency and accuracy. To address this, B-Epic, the first pipeline applying Transformer to predict BCEs is independently developed. B-Epic's robustness is validated through multiple testing datasets, including distinguishing clinically-approved vaccine targets, identifying BCEs (the Immune Epitope Database testing dataset; n = 23,888) and immunoreactive peptides (Trypanosoma cruzi peptidome; n = 239,575) with high AUCs of 0.882 and 0.945, respectively, outperforming widely used tools. Based on its superior performance, B-Epic is applied to the prevention of carcinogenic pathogens. In the application to Helicobacter pylori, peptides screened by B-Epic can activate B cells in experiments, suggesting their potential as vaccine targets. In another application to Epstein-Barr virus, B-Epic identifies pan-immunoreactive peptides in a clinical cohort (n = 899). These peptides exhibit higher reactogenicity in nasopharyngeal carcinoma patients than in healthy controls (n = 140), indicating their viability as immunodiagnostic targets. Overall, B-Epic utilizes self-attention, high-dimensional feature projection, and convolutional neural networks to autonomously extract complicated BCE features, enabling accurate BCE prediction and thereby facilitating efforts to prevent infectious diseases and cancers.

Indexed as

B-LymphocytesEpitopes, B-LymphocyteImmunodominant EpitopesVaccine DevelopmentHumansEpitopes, B-LymphocyteImmunodominant EpitopesB cell epitope predictionImmunodiagnostics designpathogens preventiontransformervaccines development

Identifiers

PMID41054859
PMCPMC12713022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.